Nerivio, FGD000075-4.7
Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine. 510(k) K203181, from Theranica Bioelectronics , Ltd. (Netanya, IL). Product code QGT, class 2.
As of Nov 21, 2026, K203181 is an FDA 510(k) held by Theranica Bioelectronics , Ltd., substantially equivalent on Jan 22, 2021 after 88 days, with no recalls tied to it in FDA's recall database.
- Review time: 88 days
- Recalls: 0
- Cited as a predicate by: 1 device
The Nerivio is indicated for acute treatment of migraine with or without aura in patients 12 years of age or older. It is a
- NerivioK201824 · Theranica Bio-Electronics, Ltd. · Oct 23, 2020
- Valutrode Neurostimlation ElectrodesK130987 · Axelgaard Mfg. Co., Ltd. · Jul 17, 2013
- NerivioK223169 · Theranica Bioelectronics , Ltd. · Feb 6, 2023
- Nerivio; Nerivio InfinityK250405 · Theranica Bio-Electronics, Ltd. · May 14, 2025
- Nerivio; NerivioInfinityK241756 · Theranica Bio-Electronics, Ltd. · Oct 8, 2024
- NerivioInfinityK232152 · Theranica Bioelectronics , Ltd. · Nov 8, 2023
- NerivioK223169 · Theranica Bioelectronics , Ltd. · Feb 6, 2023
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Oct 26, 2020
- Review panel
- Neurology
- Regulation
- 21 CFR 882.5899
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files